TNFRSF6B and Crohn disease: The TNFRSF6B level was causally linked to a reduced risk of inflammatory bowel disease and its subtypes (inflammatory bowel disease (A294), P = 4.00 × 10–20, Benjamini–Hochberg FDR = 9.19 × 10–19; Crohn’s disease (A12), P = 1.18 × 10–16, Benjamini–Hochberg FDR = 1.82 × 10–15; ulcerative colitis (A970), P = 2.14 × 10–8, Benjamini–Hochberg FDR = 7.56 × 10–8).